Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-6.92 Insider Own2.30% Shs Outstand346.24M Perf Week-9.28%
Market Cap2.98B Forward P/E1.84 EPS next Y4.67 Insider Trans-69.97% Shs Float338.25M Perf Month-20.81%
Income-2409.00M PEG- EPS next Q0.91 Inst Own66.80% Short Float13.58% Perf Quarter-38.53%
Sales9.67B P/S0.31 EPS this Y-714.90% Inst Trans20.32% Short Ratio2.47 Perf Half Y-61.02%
Book/sh9.01 P/B0.95 EPS next Y19.00% ROA-5.20% Target Price- Perf Year-76.10%
Cash/sh1.57 P/C5.49 EPS next 5Y12.95% ROE-52.70% 52W Range8.36 - 38.50 Perf YTD-40.77%
Dividend- P/FCF1.66 EPS past 5Y61.43% ROI-1.60% 52W High-77.66% Beta-0.09
Dividend %- Quick Ratio1.10 Sales past 5Y31.90% Gross Margin73.00% 52W Low2.87% ATR0.40
Employees21500 Current Ratio1.40 Sales Q/Q-12.20% Oper. Margin-5.90% RSI (14)22.14 Volatility4.97% 3.88%
OptionableYes Debt/Eq9.47 EPS Q/Q-41.70% Profit Margin-24.90% Rel Volume0.84 Prev Close8.51
ShortableYes LT Debt/Eq9.47 EarningsMay 09 BMO Payout- Avg Volume18.60M Price8.60
Recom3.00 SMA20-13.22% SMA50-28.83% SMA200-53.94% Volume15,661,824 Change1.06%
Apr-20-17Reiterated JP Morgan Neutral $15 → $10
Mar-23-17Reiterated RBC Capital Mkts Sector Perform $21 → $18
Mar-06-17Reiterated Rodman & Renshaw Neutral $23 → $17
Feb-27-17Reiterated Mizuho Underperform $11 → $9
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
Aug-10-16Reiterated Piper Jaffray Underweight $19 → $22
Apr-24-17 04:04PM  Rite Aid, DryShips Stumble into Mondays 52-Week Low Club 24/7 Wall St.
08:15AM  Blog Coverage: Valeant Announces the Pricing for SILIQ as the Lowest Priced Injectable Biologic for Moderate-To-Severe Plaque Psoriasis Accesswire
Apr-23-17 09:40AM  The Scariest Prescription Drug Price Chart You'll Ever See Motley Fool
Apr-22-17 02:12PM  Why Now Is Not the Time to Buy Valeant Pharmaceuticals Motley Fool
Apr-21-17 04:43PM  Valeant Shares Plummet as Debt Issues Remain Unsolved, Prices New Psoriasis Drug TheStreet.com
04:27PM  Why Valeant Pharmaceuticals, Manhattan Associates, and NCR Slumped Today Motley Fool
01:36PM  1 Current and 1 Former Healthcare CEO Who Deserve Far More Flak Than United Airlines' Oscar Munoz Motley Fool
12:28PM  Valeant Pharmaceuticals: Not Worth the Risk! Barrons.com
11:26AM  Jim Cramer -- Valeant's Not Worth the Speculation TheStreet.com
09:55AM  Cramer's Stop Trading: Valeant CNBC Videos
09:36AM  Valeant prices psoriasis treatment at $3,500 per month Reuters
07:53AM  Valeant prices psoriasis treatment at $3,500 per month Reuters
07:46AM  Valeant says its plaque psoriasis drug will cost $3,500 a month MarketWatch
07:30AM  Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis PR Newswire
Apr-20-17 10:34AM  Valeant: Will Earnings Even Matter? Barrons.com
08:36AM  4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings Zacks
Apr-19-17 07:30AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Valeant Pharmaceuticals Accesswire
07:00AM  [$$] Investors bet on Incyte drug success Financial Times
Apr-18-17 10:00AM  How Drug-Company 'Benevolence' Silences the Sick Bloomberg -5.59%
Apr-13-17 10:21AM  Valeant Pharmaceuticals' Market Cap Is Now Lower Than Its Projected Full-Year EBITDA Motley Fool
Apr-10-17 05:00PM  Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call PR Newswire
05:00PM  Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call CNW Group
01:00AM  Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views TheStreet.com
Apr-09-17 03:55PM  Valeant: It's Not a Game of Chess - Part IV GuruFocus.com
Apr-07-17 04:04PM  Valeant, DryShips Stuck in Fridays 52-Week Low Club 24/7 Wall St.
01:41PM  Why Valeant Just Popped Barrons.com
10:25AM  Valeant Shares on Pace to Finish Week at Lowest Level Since 2008 TheStreet.com
08:15AM  Blog Coverage Valeant's Bausch + Lomb Receives FDA Clearance for Vision Enhancement System Accesswire
Apr-06-17 04:04PM  Valeant, DryShips Dont Escape Thursdays 52-Week Low Club 24/7 Wall St.
09:49AM  Valeant's Merry-Go-Round of Disappointment Won't Stop Bloomberg
09:23AM  Can Valeant Pharmaceuticals Regain Its Mojo? Motley Fool
07:30AM  Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite Next-Generation Phacoemulsification Platform PR Newswire
Apr-05-17 04:19PM  Valeant trades in below $10 for first time since 2008 CNBC -6.59%
04:04PM  Valeant, DryShips Plunge into Wednesdays 52-Week Low Club 24/7 Wall St.
04:03PM  Valeant Shares Close Below $10 for First Time Since 2008 TheStreet.com
01:53PM  Valeant (VRX) Stock Continues to Slump: Should You Buy the Dip? Zacks
12:59PM  Valeant Pharmaceuticals Is In Hat-Size Territory Investopedia
12:46PM  Valeant Tumbles Below $10 on Struggle to Sell Assets, Raise Cash Bloomberg
11:18AM  Valeant (VRX) Faces Pricing Issues, Generic Threats Loom Zacks
09:57AM  Why Valeant is Crashing Barrons.com
Apr-04-17 03:41PM  4 Reasons Valeant Pharmaceuticals Int'l Inc. Nosedived 23% in March Motley Fool
03:25PM  Moody's Liquidity-Stress Index dips again in March; markets remain supportive of US speculative-grade companies Moody's
01:55PM  Valeant Plummets After Revealing Jaw-Dropping Payday for Its CEO
Apr-03-17 12:50PM  Valeant: It Is Not a Game of Chess - Part III -5.08%
10:42AM  Valeant Pharmaceuticals Still Searches for a Bottom
08:00AM  Bill Ackman Just Gave Up on Valeant. Should You Too? at Motley Fool
Mar-31-17 06:15PM  Bill Ackman's Mea Culpa Cited These 3 Factors for Valeant's Downfall at Motley Fool
07:40AM  Why Is Valeant (VRX) Down 17.7% Since the Last Earnings Report?
Mar-30-17 09:10PM  Cenovus Falls After Conoco Deal, Valeant Resumes Decline: Most Active Stocks, March 30
04:43PM  Ackman to hedge fund clients: 'Deeply and profoundly sorry' for Valeant at bizjournals.com
03:07PM  Why Its So Hard for Activist Investors to Find Value
02:47PM  Ackman Reflects on His Valeant Investment
01:45PM  Bill Ackman Releases Annual Letter, Apologizes for Losing All That Money
12:35PM  Bill Ackman Apologizes for Valeant Investment Error
12:35PM  Bill Ackman Apologizes for Valeant Investment Error at Investopedia
10:48AM  Valeant Pharmaceuticals International, Inc -- Moody's raises Valeant's SGL to SGL-2; affirms existing ratings; negative outlook at Moody's
10:13AM  Pershing Square's Bill Ackman is Really, Really, Really Sorry at Barrons.com
09:58AM  Ackman Says He's Sorry For Valeant Investment
09:09AM  The Ultimate Kick in the Pants: Valeant's Former CEO Is Suing the Company at Motley Fool
08:55AM  Bill Ackman To Investors: 'Deeply And Profoundly' Sorry For The Valeant Fiasco
08:51AM  What Makes Valeant Pharmaceuticals (VRX) a Strong Sell?
08:51AM  What Makes Valeant Pharmaceuticals (VRX) a Strong Sell? at Investopedia
07:30AM  Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced PR Newswire
07:27AM  Bill Ackman apologizes for $4 billion Valeant mistake (finally) at MarketWatch
07:09AM  5 Things You Must Know Before the Market Opens Thursday
Mar-29-17 07:32PM  Valeant Investment Was a 'Huge Mistake' at Investopedia
06:27PM  Ackman apologizes for Valeant losses, calls bet a mistake
04:16PM  Ackman Is 'Profoundly' Sorry for $4 Billion Valeant 'Mistake'
03:47PM  Here's the Bill Ackman apology Wall Street's been waiting for
12:58PM  Valeant's Banks Extend a Lifeline
11:46AM  Shares of Valeant Rise as 2018 Debt Maturities Extended at Barrons.com
10:40AM  Roundtable: 1 Stock I Wont Touch With a 10-Foot Pole at Motley Fool
10:40AM  3 Stocks We Won't Touch With a 10-Foot Pole at Motley Fool
08:43AM  Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock?
08:43AM  Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock? at Investopedia
Mar-28-17 05:54PM  Behind the Bill Ackman Controversies
05:30PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial
11:07AM  Orexigen Inks Commercialization Deal for Contrave, Stock Up
09:12AM  Former Valeant CEO Files Suit Against the Company
Mar-27-17 08:52PM  Valeant Ex-CEO Pearson Sues Drugmaker Over Withheld Shares
06:42PM  Former Valeant CEO sues company over unmade compensation -WSJ Reuters
06:02PM  [$$] Valeant Former CEO Sues Company Over Unmade Payments at The Wall Street Journal
12:43PM  TransDigm: The End is Nigh? at Barrons.com
09:30AM  Drug Manufacturers Continue to be Plagued by Pricing Concerns: Today's Research Reports on Valeant Pharmaceuticals and Mylan Accesswire
07:36AM  Vyzulta May Be a Potent Therapy for Glaucoma in the Future
Mar-25-17 02:01PM  Can You Guess Which Drugmaker Has the Most Debt? (Hint: It's Not Valeant) at Motley Fool
Mar-24-17 05:45PM  Johnson & Johnson's CEO Believes Trump Is Missing the Point on Drug-Price Reform at Motley Fool
01:52PM  Francis Chou Comments on Valeant
01:48PM  Chou Opportunity Fund 4th Quarter Message to Shareholders
10:35AM  Bausch & Lomb Continues to be Key Growth Driver for Valeant
09:05AM  Valeants Diversified Products Revenue May Drop in 2017
07:35AM  Valeant Pharmaceuticals is Developing its Sales Force
Mar-23-17 09:15PM  The 'Dogs' of Wall Street: Here's a Look at Some of the Worst Performing Stocks of the Year
02:47PM  A Safer Way to Play Valeant and Community Health at Barrons.com
11:05AM  'Female Viagra' founder: GOP health bill would hurt the 'sexual revolution'
10:49AM  Valeant CEO Compensation Revealed, Shares Climb
10:35AM  Siliq May be a Strong Growth Driver for Valeant in 2017
10:26AM  Bill Ackman Is Back at the Sohn Investment Conference This Year at The Wall Street Journal
10:16AM  Valeant: Room to Move? at Barrons.com
09:06AM  New Product Launches May Boost Valeants Dermatology Revenue
Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September, 2010. The company was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DE SCHUTTER RICHARD UDirectorMar 15Buy10.8010,000108,00025,190Mar 16 05:12 PM
Herendeen PaulEVP and CFOMar 14Buy10.7224,000257,280174,000Mar 16 05:04 PM
ValueAct Holdings, L.P.DirectorMar 14Buy10.823,000,00032,465,00016,937,431Mar 16 04:31 PM
Pershing Square Capital ManageDirectorMar 13Sale11.0018,114,432199,258,7520Mar 14 04:14 PM
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM